- Home
- TRUG vs EDSA Comparison
TRUG vs EDSA Comparison
Compare TRUG & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRUG
- EDSA
- Stock Information
- Founded
- TRUG 1983
- EDSA 2015
- Country
- TRUG United States
- EDSA Canada
- Employees
- TRUG N/A
- EDSA N/A
- Industry
- TRUG
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- TRUG
- EDSA Health Care
- Exchange
- TRUG NYSE
- EDSA Nasdaq
- Market Cap
- TRUG 12.7M
- EDSA 13.7M
- IPO Year
- TRUG N/A
- EDSA N/A
- Fundamental
- Price
- TRUG $0.95
- EDSA $4.28
- Analyst Decision
- TRUG
- EDSA Strong Buy
- Analyst Count
- TRUG 0
- EDSA 2
- Target Price
- TRUG N/A
- EDSA $39.00
- AVG Volume (30 Days)
- TRUG 11.3K
- EDSA 8.9K
- Earning Date
- TRUG 10-15-2024
- EDSA 08-09-2024
- Dividend Yield
- TRUG N/A
- EDSA N/A
- EPS Growth
- TRUG N/A
- EDSA N/A
- EPS
- TRUG N/A
- EDSA N/A
- Revenue
- TRUG $19,112,071.00
- EDSA N/A
- Revenue This Year
- TRUG N/A
- EDSA N/A
- Revenue Next Year
- TRUG N/A
- EDSA N/A
- P/E Ratio
- TRUG N/A
- EDSA N/A
- Revenue Growth
- TRUG N/A
- EDSA N/A
- 52 Week Low
- TRUG $0.79
- EDSA $2.46
- 52 Week High
- TRUG $11.82
- EDSA $8.33
- Technical
- Relative Strength Index (RSI)
- TRUG 41.33
- EDSA 45.00
- Support Level
- TRUG $0.79
- EDSA $4.20
- Resistance Level
- TRUG $1.03
- EDSA $5.00
- Average True Range (ATR)
- TRUG 0.11
- EDSA 0.23
- MACD
- TRUG -0.01
- EDSA 0.01
- Stochastic Oscillator
- TRUG 34.98
- EDSA 14.29
About TRUG TRUGOLF HOLDINGS INC
TruGolf Holdings Inc is a indoor golf gaming solutions company. It has built video games ("Links"), innovative hardware solutions, and an all-new e-sports platform to connect golfers around the world with E6 CONNECT.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.